The Off-Label Use of Selective Serotonin Reuptake Inhibitors for Sexual Behavior Management: Risks and Considerations

In this study, mild improvements in erectile function, penile sensitivity, and nocturnal erections were observed in male patients with post-drug syndrome following a 16-week treatment targeting the peripheral nerves of the genitalia, but significant symptoms persisted, indicating further research is essential.

This study suggests that post-finasteride syndrome and post-SSRI sexual dysfunction share potential etiopathogenetic mechanisms involving brain modulators, neurotransmitters, and gut microbiota, although more research is needed to understand these conditions fully.

This study found that males treated with serotonergic antidepressants had an increased risk of erectile dysfunction, with an adjusted odds ratio of 3.2, and the risk for post-SSRI sexual dysfunction was 0.46%, emphasizing the importance of informed consent due to these potential irreversible side effects.

This paper describes the development of diagnostic criteria for several enduring sexual dysfunction conditions following the use of certain medications, highlighting common sexual and non-sexual symptoms.

This review discusses adverse effects of 5 alpha-reductase inhibitors, particularly persistent side effects such as post-finasteride syndrome, and highlights the need for further investigation.

This study found that patients with post-finasteride syndrome exhibited major depressive disorder, severe erectile dysfunction, and neuropathy, alongside altered neuroactive steroid levels in cerebrospinal fluid.

This study reports that clinical trials of finasteride for androgenic alopecia provide insufficient and systematically biased safety data, with most participants unrepresentative of those in pivotal trials that led to FDA approval.